Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

Claims 1 to 18 (canceled).

Claim 19 (previously presented). A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of the formula:



wherein

X is O or S;

Q is O or S;

n is an integer from 1 to 5;

R_1 and R_2 are independently selected from the group consisting of H, substituted or unsubstituted straight or branched alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted at least partially saturated cycloalkyl, and substituted or unsubstituted cycloheteroalkyl, with the proviso that R_1 and R_2 are not both hydrogen,

wherein each Ra member is independently selected from the group consisting of unsubstituted saturated alkyl, unsubstituted heteroalkyl, unsubstituted alkenyl, unsubstituted alkynyl, unsubstituted at least partially saturated cycloalkyl, unsubstituted ketoalkyl, unsubstituted hydroxyalkyl, unsubstituted aminoalkyl, $-CH_2-NR_3R_4$, unsubstituted alkoxy, halo, unsubstituted haloalkyl, cyano, hydroxy, nitro, amino, unsubstituted carboxamido, $-CONR_3R_4$,

$-NR_3R_4$, sulfonamido, $-SO_2NR_3R_4$, $-C(O)R_6$, $-SR_5$, $-SO_2R_6$, $-S(O)R_6$, $-NR_6C(O)R_7$, and $-NR_6SO_2R_7$,

wherein R_3 and R_4 are selected from the group consisting of hydrogen, unsubstituted saturated alkyl, unsubstituted alkenyl, unsubstituted alkynyl, unsubstituted heteroalkyl, unsubstituted at least partially saturated cycloalkyl, unsubstituted hydroxyalkyl and imino-methylamino and optionally R_3 and R_4 may be taken together with the N atom to which they are attached to form a 5-7 membered ring; and R_5, R_6 and R_7 are independently selected from the group consisting of hydrogen, unsubstituted saturated alkyl and unsubstituted saturated heteroalkyl;

or a pharmaceutically acceptable salt thereof.

Claim 20 (previously presented). The composition of claim 19, wherein X is O; Q is O; and n is 1.

Claim 21 (previously presented). The composition of claim 19, wherein X is O; Q is O and n is 1, 2 or 3.

Claim 22 (original). The composition of claim 21, wherein at least one of R_1 and R_2 is H.

Claim 23 (previously presented). The composition of claim 22, wherein R_1 is unsubstituted C_1-C_8 homoalkyl, C_1-C_8 heteroalkyl, or C_3-C_8cycloalkyl.

Claim 24 (previously presented). The composition of claim 22, wherein R_1 is methyl, ethyl, *n*-propyl, *i*-propyl, *n*-butyl, *sec*-butyl, *tert*-butyl, pentyl, hexyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentenyl, cyclohexenyl, or cycloheptenyl.

Claim 25 (original). The composition of claim 24, wherein R_1 is cyclohexyl.

Claim 26 (original). The composition of claim 19, wherein R_1 is a substituted or unsubstituted piperidinyl, furyl, furfuryl, furanyl, thiofuranyl, and morpholinyl.

Claim 27 (previously presented). The composition of claim 24, wherein R_1 is fully saturated cyclohexyl.

Claim 28 (previously presented). The composition of claim 27, wherein the compound is of the formula:



wherein Ra_1 and Ra_2 are independently selected from the group consisting of unsubstituted saturated alkyl, unsubstituted alkenyl, unsubstituted alkynyl, unsubstituted at least partially saturated cycloalkyl, unsubstituted ketoalkyl, unsubstituted hydroxyalkyl, unsubstituted aminoalkyl, $-CH_2-NR_3R_4$, unsubstituted alkoxy, halo, unsubstituted haloalkyl, cyano, hydroxy, nitro, amino, $-NR_3R_4$, unsubstituted carboxamido, $-CONR_3R_4$, sulfonamido, $-SO_2NR_3R_4$; $-C(O)R_6$, $-SR_5$, $-SO_2R_6$, $-S(O)R_6$, $-NR_6C(O)R_7$, and $-NR_6SO_2R_7$;

wherein R_3 and R_4 are independently selected from the group consisting of H, unsubstituted alkyl, unsubstituted alkenyl, unsubstituted alkynyl, unsubstituted cycloalkyl, unsubstituted hydroxyalkyl and imino-methylamino and optionally R_3 and R_4 may be taken together with the N atom to which they are attached to form a 5-7 membered ring; and R_5, R_6 and R_7 are independently selected from the group consisting of hydrogen, unsubstituted alkyl, and unsubstituted heteroalkyl.

Claim 29 (previously presented). The composition of claim 27, wherein the compound is of the formula:



or



wherein Ra_1 is selected from the group consisting of unsubstituted saturated alkyl, unsubstituted alkenyl, unsubstituted alkynyl, unsubstituted at least partially saturated cycloalkyl, unsubstituted ketoalkyl, unsubstituted hydroxyalkyl, unsubstituted aminoalkyl, $-CH_2-NR_3R_4$, unsubstituted alkoxy, halo, unsubstituted haloalkyl, cyano, hydroxy, nitro, amino, $-NR_3R_4$, unsubstituted carboxamido, $-CONR_3R_4$, sulfonamido, $-SO_2NR_3R_4$, $-C(O)R_6$, $-SR_5$, $-SO_2R_6$, $-S(O)R_6$, $-NR_6C(O)R_7$, and $-NR_6SO_2R_7$;

wherein R_3 and R_4 are independently selected from the group consisting of H, unsubstituted alkyl, unsubstituted alkenyl, unsubstituted alkynyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted hydroxyalkyl and imino-methylamino and optionally R_3 and R_4 may be taken together with the N atom to which they are attached to form a 5-7 membered ring; and R_5, R_6 and R_7 are independently selected from the group consisting of hydrogen, alkyl, and heteroalkyl.

Claim 30 (original). The composition of claim 29, wherein Ra_1 is selected from the group consisting of $-C(O)NH_2$, $-C(O)CH_3$, or $-(CH_2)_2OH$.

Claim 31 (previously presented). The composition of claim 21, wherein-each Ra member is independently selected from the group consisting of unsubstituted saturated alkyl, unsubstituted heteroalkyl, unsubstituted alkenyl, unsubstituted alkynyl, unsubstituted at least partially saturated cycloalkyl, unsubstituted ketoalkyl, unsubstituted hydroxyalkyl, unsubstituted aminoalkyl, $-CH_2-NR_3R_4$, unsubstituted alkoxy, halo, unsubstituted haloalkyl, cyano, hydroxy, nitro, amino, $-NR_3R_4$, unsubstituted carboxamido, $-CONR_3R_4$, sulfonamido, and $-SO_2NR_3R_4$ and

wherein R_3 and R_4 are independently selected from the group consisting of H, unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted alkenyl, unsubstituted alkynyl, unsubstituted cycloalkyl, unsubstituted hydroxyalkyl and imino-methylamino and optionally R_3 and R_4 may be taken together with the N atom to which they are attached to form a 5-7 membered ring; and R_5, R_6 and R_7 are independently selected from the group consisting of hydrogen, unsubstituted alkyl, and unsubstituted heteroalkyl.

Claim 32 (previously presented). The composition of claim 19, wherein the compound is N-cyclohexyl 3'-carboxamido biphenyl-3-yl carbamate.

Claim 33 (previously presented). The composition of claim 31, wherein R_1 is H and R_2 is C_3-C_8 cycloalkyl.

Claim 34 (currently amended). A method of treating a mammal for anxiety, depression, or pain, or any combination thereof, ~~inhibiting fatty acid amide hydrolase activity in a mammal~~, said method comprising administering to ~~the~~ a mammal in need thereof an inhibitor of fatty acid amide hydrolase which is ~~a~~ compound of the formula:



wherein

X is O or S;

Q is O or S;

n is an integer from 1 to 5;

R_1 and R_2 are independently selected from the group consisting of H, substituted or unsubstituted straight or branched alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted at least partially saturated cycloalkyl, and substituted or unsubstituted cycloheteroalkyl, with the proviso that R_1 and R_2 are not both hydrogen;

wherein each Ra member is independently selected from the group consisting of unsubstituted saturated alkyl, unsubstituted heteroalkyl, unsubstituted alkenyl, unsubstituted alkynyl, unsubstituted at least partially saturated cycloalkyl, unsubstituted ketoalkyl, unsubstituted hydroxyalkyl, unsubstituted aminoalkyl, $-CH_2-NR_3R_4$, unsubstituted alkoxy, halo, unsubstituted haloalkyl, cyano, hydroxy, nitro, amino, unsubstituted carboxamido, $-CONR_3R_4$,$-NR_3R_4$, sulfonamido, $-SO_2NR_3R_4$, $-C(O)R_6$, $-SR_5$, $-SO_2R_6$, $-S(O)R_6$, $-NR_6C(O)R_7$, and $-NR_6SO_2R_7$,

wherein R_3 and R_4 are selected from the group consisting of hydrogen, unsubstituted saturated alkyl, unsubstituted alkenyl, unsubstituted alkynyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted hydroxyalkyl and imino-methylamino and optionally R_3 and R_4 may be taken together with the N atom to which they are attached to form a 5-7 membered ring; and R_5, R_6 and R_7 are independently selected from the group consisting of hydrogen, unsubstituted saturated alkyl and unsubstituted saturated heteroalkyl;

or a pharmaceutically acceptable salt thereof.

Claim 35 (original). The method of claim 34, wherein the mammal is human.

Claim 36 (original). The method of claim 34, wherein the compound is administered orally.

Claim 37 (previously presented). The method of claim 34, wherein n is 1, 2, or 3, R_2 is H, and R_1 is unsubstituted C_1-C_8 homoalkyl, unsubstituted C_1-C_8 heteroalkyl, or unsubstituted C_3-C_8 cycloalkyl.

Claim 38 (previously presented). The method of claim 34, wherein R_2 is hydrogen, and R_1 is fully saturated cyclohexyl.

Claim 39 (previously presented). The pharmaceutical composition of claim 21, wherein n is 1 or 2.

Claim 40 (previously presented). The composition of claim 39, wherein the compound is of a formula selected from the group consisting of:



,



and



wherein each Ra member is independently selected from the group consisting of unsubstituted saturated alkyl, unsubstituted heteroalkyl, unsubstituted alkenyl, unsubstituted alkynyl, unsubstituted at least partially saturated cycloalkyl, unsubstituted ketoalkyl, unsubstituted hydroxyalkyl, unsubstituted aminoalkyl, -CH_2-NR_3R_4, unsubstituted alkoxy, halo, unsubstituted haloalkyl, cyano, hydroxy, nitro, amino, unsubstituted carboxamido, -$CONR_3R_4$, -NR_3R_4, sulfonamido, -$SO_2NR_3R_4$, -$C(O)R_6$, -SR_5, -SO_2R_6, -$S(O)R_6$, -$NR_6C(O)R_7$, and -$NR_6SO_2R_7$,

wherein R_3 and R_4 are selected from the group consisting of hydrogen, unsubstituted saturated alkyl, unsubstituted alkenyl, unsubstituted alkynyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted hydroxyalkyl and imino-methylamino and optionally R_3 and R_4 may be taken together with the N atom to which they are attached to form a 5-7 membered ring; and R_5, R_6 and R_7 are independently selected from the group consisting of hydrogen, unsubstituted saturated alkyl and unsubstituted saturated heteroalkyl.

Claim 41 (previously presented). The composition of claim 40, wherein R_2 is selected from the group consisting of substituted or unsubstituted straight or branched alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted at least partially saturated cycloalkyl, and substituted or unsubstituted cycloheteroalkyl, and optionally R_1 and R_2, may be taken together with the N atom to which they are attached to form a substituted or unsubstituted ring.

Claim 42 (previously presented). The composition of claim 41 wherein each Ra member is independently selected from the group consisting of unsubstituted saturated alkyl, unsubstituted heteroalkyl, unsubstituted alkenyl, unsubstituted alkynyl, unsubstituted at least partially saturated cycloalkyl, unsubstituted ketoalkyl, unsubstituted hydroxyalkyl, unsubstituted aminoalkyl, $-CH_2-NR_3R_4$, unsubstituted alkoxy, halo, unsubstituted haloalkyl, cyano, hydroxy, nitro, amino, $-NR_3R_4$, SR_5, unsubstituted carboxamido, $-CONR_3R_4$, -sulfonamido, and $-SO_2NR_3R_4$.

Claim 43 (previously presented). The composition of claim 42, wherein R_1 is hydrogen; and R_2 is an isomer of propyl, butyl, pentyl, hexyl, heptyl, octyl, heteroalkyl, cycloheteroalkyl, or at least partially saturated cycloalkyl.

Claim 44 (previously presented). The composition of claim 43 wherein R_2 is at least partially saturated cycloalkyl or cycloheteroalkyl.

Claim 45 (previously presented). The composition of claim 43 wherein the R_2 member is fully saturated and an isomer of pentyl, hexyl, heptyl, or octyl.

Claim 46 (previously presented). The composition of claim 44, wherein the R_2 member is a fully saturated cycloalkyl.

Claim 47 (previously presented). The composition of claim 41, wherein at least one of R_1 and R_2 is H.

Claim 48 (previously presented). The composition of claim 44, wherein each Ra is independently selected from the group consisting of $-C(O)NH_2$, $-C(O)CH_3$, $-(CH_2)_2OH$, $-SO_2NH_2$, $-CH_2OH$, $-CF_3$, $-CH_2CH_3$,$-CH_3$, n-C_3H_7, $-NH_2$, F, $-NO_2$, -CN and -OH.

Claim 49 (previously presented). The composition of claim 39, wherein the compound is of the formula:



Claim 50 (previously presented). The composition of claim 49, wherein Ra_1 is selected from the group consisting of $-C(O)NH_2$, $-C(O)CH_3$, $-(CH_2)_2OH$, $-SO_2NH_2$, $-CH_2OH$, – CF3, $-CH_3$, $-CH_2CH_3$, n-C_3H_7, $-NH_2$, -F, $-NO_2$, –CN, and -OH.

Claim 51 (previously presented). The composition of claim 21, wherein there is at least one Ra member at the meta position.

Claim 52 (previously presented). The composition of claim 21, wherein n is 2.

Claim 53 (previously presented). The composition of claim 19, wherein R_1 and R_2 are independently selected from the group consisting of hydrogen, substituted or unsubstituted at least partially saturated cycloalkyl, and substituted or unsubstituted cycloheteroalkyl, with the proviso that R_1 and R_2 are not both hydrogen.

Claim 54 (previously presented). A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of the formula:



wherein

X is O or S;

Q is O or S;

R is substituted or unsubstituted meta-biphenyl; and

R_1 and R_2 are independently selected from the group consisting of hydrogen, substituted or unsubstituted at least partially saturated cycloalkyl, and substituted or unsubstituted cycloheteroalkyl, with the proviso that R_1 and R_2 are not both hydrogen.

Claim 55 (previously presented). The composition of claim 54, wherein X is O and Q is O and wherein R is unsubstituted meta biphenyl.

Claim 56 (previously presented). The composition of claim 55, wherein one of R_1 and R_2 is hydrogen.

Claim 57 (previously presented). The composition of claim 56, wherein R_1 is selected from the group consisting of unsubstituted at least partially saturated cycloalkyl and unsubstituted cycloheteroalkyl.

Claim 58 (previously presented). The composition of claim 57, wherein R_1 is an at least partially saturated cyclopentyl, cyclohexyl, cycloheptyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctyl, or cyclooctenyl.

Claim 59 (previously presented). The composition of claim 56, wherein R_1 is a saturated cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl.

Claim 60 (previously presented). The composition of claim 56, wherein R_1 is unsubstituted and is a saturated cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl.

Claim 61 (previously presented). The method of claim 34, wherein the compound is N-cyclohexyl 3'-carboxamido biphenyl-3-yl carbamate.

Claim 62 (previously presented). The method of claim 34, wherein n is 1, 2 or 3.

Claim 63 (previously presented). The method of claim 62, wherein the compound is of a formula selected from the group consisting of:



,



and



.

wherein Ra_1 and Ra_2 are independently selected from the group consisting of unsubstituted alkyl, unsubstituted alkenyl, unsubstituted alkynyl, unsubstituted cycloalkyl, unsubstituted ketoalkyl, unsubstituted hydroxyalkyl, unsubstituted aminoalkyl, $-CH_2-NR_3R_4$, unsubstituted alkoxy, halo, unsubstituted haloalkyl, cyano, hydroxy, nitro, amino, $-NR_3R_4$, unsubstituted carboxamido, -$CONR_3R_4$, sulfonamido, -$SO_2NR_3R_4$; -$C(O)R_6$, -SR_5, -SO_2R_6, -$S(O)R_6$, -$NR_6C(O)R_7$, and -$NR_6SO_2R_7$;

wherein R_3 and R_4 are independently selected from the group consisting of H, unsubstituted saturated alkyl, unsubstituted heteroalkyl, unsubstituted alkenyl, unsubstituted alkynyl, unsubstituted cycloalkyl, unsubstituted hydroxyalkyl and imino-methylamino or R_3 and optionally R_3 and R_4 may be taken together with the N atom to which they are attached to form a 5-7 membered ring; and R_5, R_6 and R_7 are independently selected from the group consisting of hydrogen, alkyl, and heteroalkyl.

Claim 64 (previously presented). The method of claim 63, wherein R_2 is independently selected from the group consisting of hydrogen, substituted or unsubstituted at least partially saturated cycloalkyl, and substituted or unsubstituted cycloheteroalkyl.

Claim 65 (currently amended). A method of treating a mammal for anxiety, depression, or pain, or any combination thereof ~~inhibiting fatty acid amide hydrolase in a mammal~~, said method comprising administering to the mammal in need thereof an inhibitor of fatty acid amide hydrolase ~~a compound~~ of the formula:



wherein

X is O or S;

Q is O or S;

R is a substituted or unsubstituted meta biphenyl;

R_1 and R_2 are independently selected from the group consisting of hydrogen, substituted or unsubstituted at least partially saturated cycloalkyl, and substituted or unsubstituted cycloheteroalkyl, with the proviso that R_1 and R_2 are not both hydrogen.

Claim 66 (previously presented). The method of claim 65, wherein X is O and Q is O and the R_2 member is a fully saturated cycloalkyl.

Claim 67 (previously presented). The method of claim 66, wherein at least one of R_1 and R_2 is H.

Claim 68 (previously presented). The method of claim 67, wherein R is unsubstituted meta biphenyl.

Claim 69 (previously presented). A compound of the formula:



wherein:

X is O or S;

Q is O or S;

n is 1, 2, or 3;

wherein each Ra member is independently selected from the group consisting of unsubstituted saturated alkyl, unsubstituted alkenyl, unsubstituted alkynyl, unsubstituted at least partially saturated cycloalkyl, unsubstituted ketoalkyl, unsubstituted hydroxyalkyl, unsubstituted aminoalkyl, $-CH_2-NR_3R_4$, unsubstituted alkoxy, halo, unsubstituted haloalkyl, cyano, hydroxy, nitro, amino, $-NR_3R_4$, unsubstituted carboxamido, $-CONR_3R_4$, sulfonamido, $-SO_2NR_3R_4$; $-C(O)R_6$, $-SR_5$, $-SO_2R_6$, $-S(O)R_6$, $-NR_6C(O)R_7$, and $-NR_6SO_2R_7$;

wherein R_3 and R_4 are independently selected from the group consisting of H, unsubstituted saturated alkyl, unsubstituted alkenyl, unsubstituted alkynyl, unsubstituted at least partially saturated cycloalkyl, unsubstituted hydroxyalkyl and imino-methylamino and wherein optionally R_3 and R_4 may together with the N atom to which they are attached combine to form a 5-7 membered ring; and R_5, R_6 and R_7 are independently selected from the group consisting of hydrogen, alkyl, and heteroalkyl;

wherein R_1 and R_2 are independently selected from the group consisting of hydrogen, substituted or unsubstituted straight or branched alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted at least partially saturated cycloalkyl, and substituted or unsubstituted cycloheteroalkyl, with the proviso that R_1 and R_2 are not both hydrogen;

and the pharmaceutically acceptable salts thereof.

Claim 70 (previously presented). The compound of claim 69, wherein the compound is of a formula selected from the group consisting of:





and



wherein Ra_1 and Ra_2 are independently selected from the group consisting of unsubstituted saturated alkyl, unsubstituted alkenyl, unsubstituted alkynyl, unsubstituted cycloalkyl, unsubstituted ketoalkyl, unsubstituted hydroxyalkyl, unsubstituted aminoalkyl, $-CH_2-NR_3R_4$, unsubstituted alkoxy, halo, unsubstituted haloalkyl, cyano, hydroxy, nitro, amino, $-NR_3R_4$, unsubstituted carboxamido, $-CONR_3R_4$, sulfonamido, $-SO_2NR_3R_4$; $-C(O)R_6$, $-SR_5$, $-SO_2R_6$, $-S(O)R_6$, $-NR_6C(O)R_7$, and $-NR_6SO_2R_7$; and

wherein R_3 and R_4 are independently selected from the group consisting of H, unsubstituted saturated alkyl, unsubstituted alkenyl, unsubstituted alkynyl, unsubstituted at least partially saturated cycloalkyl, unsubstituted hydroxyalkyl and imino-methylamino and wherein optionally R_3 and R_4 may together with the N atom to which they are attached combine to form a 5-7 membered cyclic ring; and R_5, R_6 and R_7 are independently selected from the group consisting of hydrogen, alkyl, and heteroalkyl.

Claim 71 (previously presented). The compound of claim 70, wherein R_2 is selected from the group consisting of substituted or unsubstituted straight or branched alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted at least partially saturated cycloalkyl, and substituted or unsubstituted cycloheteroalkyl.

Claim 72 (previously presented). The compound of claim 71, wherein each Ra member is independently selected from the group consisting of unsubstituted saturated alkyl, unsubstituted heteroalkyl, unsubstituted alkenyl, unsubstituted alkynyl, unsubstituted at least partially saturated cycloalkyl, unsubstituted ketoalkyl, unsubstituted hydroxyalkyl, unsubstituted aminoalkyl, $-CH_2-NR_3R_4$, unsubstituted alkoxy, halo, unsubstituted haloalkyl, cyano, hydroxy, nitro, amino, $-NR_3R_4$, $-SR_5$, unsubstituted carboxamido, $-CONR_3R_4$, sulfonamido, and $-SO_2NR_3R_4$.

Claim 73 (previously presented). The compound of claim 72, wherein R_1 is hydrogen; and R_2 is an isomer of propyl, butyl, pentyl, hexyl, heptyl, octyl, heteroalkyl, cycloheteroalkyl, or at least partially saturated cycloalkyl.

Claim 74 (previously presented). The compound of claim 70, wherein R_2 is selected from the group consisting of unsubstituted straight or branched alkyl, unsubstituted heteroalkyl, unsubstituted at least partially saturated cycloalkyl, and unsubstituted cycloheteroalkyl.

Claim 75 (previously presented). The compound of claim 73, wherein R_2 is fully saturated and an isomer of pentyl, hexyl, heptyl, or octyl.

Claim 76 (previously presented). The compound of claim 73, wherein the R_2 member is a fully saturated cycloalkyl.

Claim 77 (previously presented). The compound of claim 70, wherein at least one of R_1 and R_2 is H.

Claim 78 (previously presented). The compound of claim 74, wherein Ra_1 is selected from the group consisting of $-C(O)NH_2$, $-C(O)CH_3$, $-(CH_2)_2OH$, SO_2NH_2, CH_2OH, $-CF_3$, $-CH_3$, $-CH_2CH_3$, $n-C_3H_7$, $-NH_2$, -F, $-NO_2$, -CN and -OH.

Claim 79 (previously presented). The compound of claim 73, wherein the compound is of the formula:



Claim 80 (previously presented). The compound of claim 79, wherein Ra_1 is selected from the group consisting of $-C(O)NH_2$, $-C(O)CH_3$, $-(CH_2)_2OH$, $-SO_2NH_2$, $-CH_2OH$, $-CF_3$, $-CH_3$, $-CH_2CH_3$, $n-C_3H_7$, $-NH_2$, -F, $-NO_2$, -CN and -OH.

Claim 81 (previously presented). The compound of claim 79, wherein R_2 is selected from the group consisting of unsubstituted straight or branched alkyl, unsubstituted heteroalkyl, unsubstituted at least partially saturated cycloalkyl, and unsubstituted cycloheteroalkyl.

Claim 82 (previously presented). The compound of claim 69, wherein n is 2.

Claim 83 (previously presented). The compound of claim 69, wherein R_1 and R_2 are independently selected from the group consisting of hydrogen, substituted or unsubstituted at least partially saturated cycloalkyl, and substituted or unsubstituted cycloheteroalkyl, with the proviso that R_1 and R_2 are not both hydrogen.

Claim 84 (previously presented). A compound of the formula,



wherein

X is O or S;

Q is O or S;

R is substituted or unsubstituted meta-biphenyl;

R_1 and R_2 are independently selected from the group consisting of hydrogen, substituted or unsubstituted at least partially saturated cycloalkyl, and substituted or unsubstituted cycloheteroalkyl, with the proviso that R_1 and R_2 are not both hydrogen.

Claim 85 (previously presented). The compound of claim 84, wherein X is O and Q is O and R is unsubstituted meta biphenyl.

Claim 86 (previously presented). The compound of claim 85, wherein one of R_1 and R_2 is hydrogen.

Claim 87 (previously presented). The compound of claim 86, wherein R_1 is at least partially saturated unsubstituted C_3-C_8 cycloalkyl or unsubstituted C_3-C_8 cycloheteroalkyl.

Claim 88 (previously presented). The compound of claim 86, wherein R_1 is an at least partially saturated cyclopentyl, cyclohexyl, cycloheptyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctyl, or cyclooctenyl.

Claim 89 (previously presented). The compound of claim 88, wherein R_1 is a saturated cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl.

Claim 90 (previously presented). The compound of claim 86, wherein R_1 is unsubstituted and is a saturated cyclopentyl, cyclohexyl, or cycloheptyl.

Claim 91 (previously presented). The compound of claim 84, wherein the compound is N-cyclohexyl 3'-carboxamido biphenyl-3-yl carbamate.

Claim 92 (previously presented). The compound of claim 83, wherein the compound has an IC_{50} for inhibiting the human fatty acid amide hydrolase of less than 1 micromolar.

Claim 93 (previously presented). The compound of claim 83, wherein the compound has an IC_{50} for inhibiting the human fatty acid amide hydrolase of less than 10 nanomolar.

Claim 94 (previously presented). The compound of claim 69, wherein the compound has an IC_{50} for inhibiting the human fatty acid amide hydrolase of less than 1 micromolar.

Claim 95 (previously presented). The compound of claim 69, wherein the compound has an IC_{50} for inhibiting the human fatty acid amide hydrolase of less than 10 nanomolar.

Claim 96 (new). The method of claim 65, wherein the mammal is a human.

Claim 97 (new). The method of claim 65, wherein the administering is oral.

Claim 98 (new). The method of claim 65, wherein a depressive disorder is treated.

Claim 99 (new). The method of claim 65, wherein an anxiety disorder is treated.

Claim 100 (new). The method of claim 34, wherein a depressive disorder is treated.

Claim 101 (new). The method of claim 34, wherein an anxiety disorder is treated.

Claim 102 (new). The method of claim 34, wherein pain is treated.

Claim 103 (new). The method of claim 65, wherein pain is treated.